HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
YARW
Yarrow Bioscience Inc
YARW lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
YARW Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
YARW's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
YARW PE Valuation
YARW has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
YARW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect YARW's losses to shrink, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
YARW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$23.27 | +$21.23 |
| Q1 2026 | -$26.26 | +$22.74 |
| Q4 2025 | -$32.26 | +$14.24 |
| Q3 2023 | -$498.97 | -$111.97 |
| Q2 2023 | -$542.47 | +$69.53 |
| Q1 2023 | -$522.97 | +$305.03 |
| Q4 2022 | -$363.97 | +$914.03 |
| Q3 2022 | -$387.00 | +$216.00 |
YARW has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over YARW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over YARW on profitability, with a higher operating margin.
YARW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $97K | +41% |
| Q1 2026 | $86K | -57% |
| Q4 2025 | $130K | +55% |
| Q3 2025 | $169K | +40% |
| Q2 2025 | $69K | -65% |
| Q1 2025 | $202K | +106% |
| Q4 2024 | $84K | +11% |
| Q3 2024 | $121K | +6.1% |
YARW's revenue is recovering but still below its 2020 peak: $97,000 last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3198% | +7733 points |
| Q1 2026 | -4437% | +116 points |
| Q4 2025 | -4015% | +11188 points |
| Q3 2025 | -4611% | +6208 points |
| Q2 2025 | -10930% | -5680 points |
| Q1 2025 | -4553% | +2978 points |
| Q4 2024 | -15202% | -6213 points |
| Q3 2024 | -10819% | -5351 points |
YARW's operating margin was −3198% last quarter, up 7732 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over YARW on cash generation, producing positive trailing cash flow while its opponent burns cash.
YARW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$8.8M |
| Q1 2026 | -$4.1M | +$7.4M |
| Q3 2025 | -$7.1M | +$1.4M |
| Q2 2025 | -$10.8M | -$2.3M |
| Q1 2025 | -$11.5M | -$3.5M |
| Q3 2024 | -$8.5M | -$3.4M |
| Q2 2024 | -$8.5M | +$1.1M |
| Q1 2024 | -$8M | -$2.5M |
YARW has burned cash in almost every quarter: −$17M over the past year, against −$39M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over YARW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
YARW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.6K shares |
| 1 year | +0.3% | +2.8K shares |
| 3 years | +1247% | +794K shares |
| 5 years | +1741% | +811K shares |
| Available history | +12794% | +851K shares |
YARW has 858,000 diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $15,000 |
| Q3 2025 | $7,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
YARW Net Leverage
YARW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
YARW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 13.3 | Oversold |
YARW's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
YARW PE vs Healthcare Sector
YARW has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
YARW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.0 | 2% below |
| 20 week MA | $28.4 | 31% below |
| 50 week MA | $29.3 | 33% below |
| 100 week MA | $47.7 | 59% below |
| 200 week MA | $102.9 | 81% below |
YARW is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
YARW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18,000.0 | $6,372.0 | -65% |
| 2021 | $6,372.0 | $1,008.0 | -84% |
| 2022 | $1,008.0 | $107.0 | -89% |
| 2023 | $107.0 | $116.5 | +8.9% |
| 2024 | $116.5 | $158.5 | +36% |
| 2025 | $158.5 | $29.4 | -81% |
| 2026 YTD | $29.4 | $19.6 | -33% |
YARW has the edge over HIMS on returns for 2026, with the stronger performance.